|
ZS Pharma announces positive results from extended treatment results of hyperkalemia drug. |
 |
|
ZS Pharma: ZS003 Phase 3 Top-Line Results. Top-line results from the Extended Treatment Phase showed that ZS-9 was able to maintain a statistically significant reduction in serum potassium relative to placebo in patients over 12 days of once-daily dosing. .............................. • The trial met the Extended Treatment Phase endpoint at the 5g and 10g doses compared with placebo (P-values of 0.0075, and <0.0001, respectively). ......................................... • ZS-9 was well-tolerated at all doses tested. Overall adverse event and GI adverse event rates and severities were comparable between the placebo and ZS-9 treated patients.
|